Our Pipeline

    * We plan to initiate a pivotal 2/3 clinical trial of this product candidate as the basis for applying for marketing approval with the FDA
    ** Subcutaneous
    *** Peripheral T-cell lymphoma, cutaneous T-cell lymphoma and T-cell acute lymphoblastic leukemia